Dr Reddy’s Laboratories (RDY) has released an update.
Dr. Reddy’s Laboratories and Zydus Lifesciences have announced a partnership to co-market a biosimilar of Pertuzumab, a vital drug for treating HER2 positive breast cancer in India. The product will be marketed under two different brand names, with Zydus using Sigrima™ and Dr. Reddy’s using Womab®. This collaboration aims to enhance the accessibility of essential cancer treatments in India, offering hope for improved patient outcomes in the fight against breast cancer.
For further insights into RDY stock, check out TipRanks’ Stock Analysis page.
